在急性心力衰竭中进行原始化尿导向的利尿疗法:系统性审查和元分析
Alonzo Armani Prata1, Annie Armani Prata2, Ana Carolina Covre Coan3
1Federal University of Espírito Santo (UFES) - Campus Maruípe, Avenida Marechal Campos, 1468, Maruípe, Vitória, ES, 29043-900, Brazil. alonzo.prata@edu.ufes.br.
Critical care (London, England)
|November 5, 2025
概括
在急性心力衰竭 (AHF) 中, natriuresis 指导的利尿疗法改善了利尿和 natriuresis,并降低了急性损伤风险. 这种协议化的方法对于AHF管理来说是安全有效的.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 关键护理医学 关键护理医学
背景情况:
- 体积过载是急性心力衰竭 (AHF) 病理生理学的核心.
- 目前用于尿剂剂量和AHF监测的策略缺乏可靠的证据.
- 这项研究解决了对AHF的基于证据的尿剂管理的需要.
研究的目的:
- 为了评估 natriuresis-guided 协议的疗效和安全性,以对AHF患者的利尿剂治疗定位.
- 为了比较 natriuresis-guided治疗与标准管理对AHF治疗.
- 综合有关利尿剂反应和使用协议化治疗的临床结果的证据.
主要方法:
- 随机对照试验 (RCT) 和观察性研究的系统审查和元分析.
- 在Cochrane,PubMed和Embase数据库中搜索到2025年6月.
- 使用R版本4.4.1计算了聚合风险比率和平均差异;使用RoB 2和ROBINS-I工具评估了偏差风险.
主要成果:
- 在48小时内,原始化尿导向疗法显著增加了尿和尿液.
- 在减肥,住院,再住院或死亡率方面没有发现显著差异.
- 与血清肌素翻倍的风险降低相关,而不会增加低血或低血压.
结论:
- 在AHF中以尿导向的利尿治疗是安全的,并改善了利尿和自然尿.
- 这种方法可以降低AHF患者急性损伤的风险.
- 需要进一步的大型RCT来确认对不同人群的长期临床终点的影响.
相关概念视频
01:22Heart Failure Drugs: Diuretics
779
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
779
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695
01:22Heart Failure VI: Adjunct Therapies
243
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
243
01:22Heart Failure Drugs: β-Blockers
747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747